AJMC® in the Press, June 28, 2019

America’s Health Insurance Plans' Monday Accountable Care SmartBrief included an article from The American Journal of Managed Care^® (AJMC^®). The article, “Analysis Finds Progress in Reducing Progress on Low-Value Services Positive but Sluggish,” covered an analysis of spending on low- and high-value care from 2014 to 2016 and found that despite significant discussion about reducing low-value care, reduction has been slight.

The National Pharmaceutical Council’s Monday CER Daily Newsfeed included an article from AJMC^®’s sister site The Center for Biosimilars^®. The article, “Real-World Evidence Shows Switching Among ESAs in CKD Is Not Associated With Risks to Safety, Efficacy,” reported that no statistically significant risk in terms of lack of effectiveness or safety was found for patients who switched therapies versus those who remained on their first therapy in either the reference group or the biosimilar group.

Tuesday’s CER Newsfeed included AJMC^®’s interview with Paul Melmeyer, director of Federal Policy, National Organization for Rare Disorders, in which he discussed factors that have historically been underrepresented in value assessment frameworks for rare disease therapies.